Investigating immunity and booster responses in vaccinated individuals against measles, mumps, and rubella
A Cross-Sectional and Open Pre-Post Interventional Study Evaluating Circulating and Mucosal Humoral and Cell-Mediated Immunity Following Measles, Mumps and Rubella (MMR) Vaccination in Adults
PHASE3 · University of Zurich · NCT05894395
This study is testing how well a booster shot works for adults aged 18-49 who have already had two doses of the measles, mumps, and rubella vaccine to see if it helps improve their immunity against these diseases.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 49 Years |
| Sex | All |
| Sponsor | University of Zurich (other) |
| Locations | 2 sites (Zürich and 1 other locations) |
| Trial ID | NCT05894395 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the immunity levels of individuals who have been fully vaccinated against measles, mumps, and rubella (MMR) and to evaluate their immune response following a booster vaccination. Given the recent resurgence of these vaccine-preventable diseases, particularly in Europe, the study seeks to understand the effectiveness of the current vaccination strategy and the potential need for booster doses in adults. Participants aged 18-49 who have received two previous MMR doses will be monitored for their immune response through blood, saliva, and nasal wash samples after receiving the booster. The findings could provide critical insights into public health strategies for controlling outbreaks of these diseases.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-49 who have received exactly two doses of the MMR vaccine within the past year.
Not a fit: Patients with acute infections or those who have had hypersensitivity reactions to MMR vaccines may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved vaccination strategies and recommendations for booster doses, enhancing immunity in the population.
How similar studies have performed: Other studies have indicated waning immunity in vaccinated individuals, suggesting that this approach to evaluating booster responses is both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18-49 (inclusive) at the time of the study screening visit * Has received exactly two previous doses of MMR-containing vaccine at any point up to one calendar year prior to the study screening visit * Willing to receive a booster MMR vaccination as outlined in the study protocol * Able and willing to comply with all other study requirements (attend all study visits and provide blood, saliva, nasal wash samples at each visit as outlined) * Sufficient language (German or English) and cognitive skills * Provides written, informed consent to participate in the study Exclusion Criteria: * Acute respiratory or other infections (postpone baseline visit until resolved) * Receipt of any other vaccination less than 4 weeks prior to the baseline visit or intention to receive another vaccination within 4 weeks following the baseline visit * Previous hypersensitivity reaction following receipt of any MMR-containing vaccine or previous hypersensitivity reaction to any component of M-M-R-vaxPro * Pregnancy, lactation, or intention to become pregnant during the study * Individuals with confirmed or suspected immunosuppressive or immune-deficient state * Known current or chronic or severe disease * Receipt of blood or plasma transfusions, or administration of immune globulin (IG) less than 12 weeks prior to the baseline visit, or intention to receive IG within 4 weeks following the baseline visit * Any other significant disease, disorder, or finding which could potentially result in an increased risk to the volunteer due to participation in the study * Being enrolled in another interventional study that may interfere with the current study
Where this trial is running
Zürich and 1 other locations
- Epidemiology, Biostatistics and Prevention Institute University of Zurich — Zürich, Switzerland (RECRUITING)
- Epidemiology, Biostatistics and Prevention Institute University of Zurich — Zürich, Switzerland (RECRUITING)
Study contacts
- Principal investigator: Jan Fehr, M.D. — Department Head
- Study coordinator: Phung Lang, Ph.D.
- Email: phung.lang@uzh.ch
- Phone: +41 44 634 46 72
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mumps, Measles, Rubella